EMA Authorised: Clopidogrel Teva (hydrogen sulphate) (clopidogrel (as hydrogen sulfate)) — Teva Pharma B.V.

View source ↗

Summary

EMA authorised Clopidogrel Teva (hydrogen sulphate) for multiple cardiovascular indications including acute coronary syndrome, myocardial infarction, stroke, an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Myocardial Infarction
• Peripheral Vascular Diseases
• Stroke

Drugs mentioned

• Clopidogrel Teva (hydrogen sulphate) (clopidogrel (as hydrogen sulfate))

Snippet

Status: Authorised. Therapeutic area: Acute Coronary Syndrome;Peripheral Vascular Diseases;Myocardial Infarction;Stroke. MAH: Teva Pharma B.V.. Decision date: 08/02/2024